Turning from the provision of care to the provision of therapies and essential personal protective equipment (PPE), Mr Pourmahram and Dr Fortner focused on the wholesale supply chain and the challenges of ensuring an uninterrupted flow of crucial materials to areas with the greatest demand.

Dr Peskin, Dr Breidbart, and Mr Eyles gave an overview of the changes the novel coronavirus has prompted for managed care payers. They agreed that the unprecedented set of circumstances surrounding the pandemic has led to an opening of the floodgates to questions without immediate answers, leaving providers and payers in unfamiliar territory in a rapidly changing environment with few guideposts.

The healthcare supply channel is dependent on drug manufacturers and their innovation and production. Representing 3 of the major biopharmaceutical companies, Dr Gerberding, Mr Morrissey, and Mr Dozier discussed the drug manufacturers’ response to the COVID-19 pandemic, announcing a recent collaboration in the fight against the novel coronavirus.

Oncology nurses and nurse navigators are positioned on the front lines of cancer care, playing an integral role in patients’ battles against cancer. Ms Shockney and Ms Nevidjon discussed the rapidly changing world that oncology nurses are facing because of COVID-19.

Patient advocacy organizations regularly field and fulfill requests for assistance from patients with a serious illness, such as cancer. In the face of COVID-19, such requests have increased exponentially. Ms Goldsmith and Mr Klein outlined their organizations’ efforts to meet patients’ needs.

Mr Reff and Mr Bailey addressed the modifications that oncology pharmacies are making to keep staff and patients safe during the coronavirus pandemic.

Less than a month after California issued a stay-at-home order in response to the COVID-19 crisis, oncology practices are seeing declines in their revenue cycles. Mr Gockerman and Mr Shah analyzed the strategies needed to mitigate the downturn.

Mr McDaniel and Dr Consuelos discussed the likely long-term impact of and lessons for the healthcare industry from the COVID-19 pandemic.